1. |
Arimura T, Abe M, Shiga H, et al. Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013. J Artif Organs, 2017, 20(3): 244-251.
|
2. |
Hirasawa H, Sugai T, Ohake S, et al. Continuous hemofiltration in the treatment of anuric multiple organ failure. Artif Organs, 1990, 14(Suppl 2): 117-119.
|
3. |
Hirasawa H, Sugai T, Ohtake Y, et al. Continuous hemofiltration and hemodiafiltration in the management of multiple organ failure. Contrib Nephrol, 1991, 93(93): 42-46.
|
4. |
Kitamura N, Kako K, Igarashi K, et al. Dialysis disequilibrium syndrome on neurointensive care: the role of continuous hemodiafiltration. Kyukyuigaku, 2013(37): 1637-1641.
|
5. |
Hattori N, Oda S. Cytokine-adsorbing hemofilter: old but new modality for septic acute kidney injury. Renal Replace Ther. 2016, 41: 2.
|
6. |
Ohtake Y, Hirasawa H, Sugai T, et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol, 1991, 93(93): 215-217.
|
7. |
van de Wetering J, Westendorp RG, van der Hoeven JG, et al. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol, 1996, 7(1): 145-150.
|
8. |
Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta, 1981, 661(2): 342-345.
|
9. |
Kitawaki T, Uchino S, Kamioka E, et al. Nafamostat mesialte vs. low dose heparin for anticoagulation during continuous renal replacement therapy. J Jpn Soc Intensive Care Med, 2007, 14: 563-569.
|
10. |
Choi JY, Kang YJ, Jang HM, et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine (Baltimore), 2015, 94(52): e2392.
|
11. |
Hwang SD, Hyun YK, Moon SJ, et al. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int J Artif Organs, 2013, 36(3): 208-216.
|
12. |
Makino S, Egi M, Kita H, et al. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J Artif Organs, 2016, 39(1): 16-21.
|
13. |
Maruyama H, Miyakawa Y, Gejyo F, et al. Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient. Nephron, 1996, 74(2): 468-469.
|
14. |
Yamazato M, Mano R, Oshiro-Chinen S, et al. Severe abdominal pain associated with allergic reaction to nafamostat mesilate in a chronic hemodialysis patient. Intern Med, 2002, 41(10): 864-866.
|
15. |
厚生労働省. 重篤副作用疾患別対応マニュアル: アナフィラキシー.(2010-06-25) [2018-06-01]. http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1h01.pdf.
|
16. |
Kamo A, Abe T, Magono S, et al. A case of nafamostat mesilate hypersensitivity with an acute and atypical change in blood volume variations during hemodialysis. J Jpn Soc Blood Purif Crit Care, 2013(4): 168-171.
|
17. |
Kim HS, Lee KE, Oh JH, et al. Cardiac arrest caused by nafamostat mesilate. Kidney Res Clin Pract, 2016, 35(3): 187-189.
|
18. |
Hirayama T, Nosaka N, Okawa Y, et al. AN69T membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective. J Intensive Care, 2017, 5: 46.
|
19. |
Kunimoto Y, Hara Y, Kawaji T, et al. The influence of nafamostat mesilate administration on the lifetime of AN69ST-continuous hemofiltration. J Jpn Soc Blood Purif Crit Care, 2017(8): 48-53.
|
20. |
Iwama H, Watanabe K, Obara S. In vitro relationship between the blood nafamostat concentration and activated coagulation time. Can J Anaesth, 2003, 50(6): 621-622.
|
21. |
Akizawa T, Kosikawa S, Iwamoto S, et al. Pharmacokinetic studies of regional anticoagulant-FUT-175 in hemodialysis. Kidney Dial, 1989, 26: 145-151.
|
22. |
Inoue Y, Tsychihashi Y, Ohsaka M, et al. Optimal target of ACT for an appropriate nafamostat mesilate dosage during continuous renal replacement therapy. J Jpn Soc Blood Purif Crit Care, 2010(1): 124-130.
|
23. |
Miyatake Y, Makino S, Kubota K, et al. Association between intra-circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using nafamostat mesilate:
a retrospective pilot observational study. Kobe J Med Sci, 2017, 63: E30-E36.
|
24. |
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl, 2012, 2(1): 1-138.
|
25. |
Liu C, Mao Z, Kang H, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critical ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crti Care, 2016, 20: 144.
|
26. |
Stucker F, Ponte B, Tataw J, et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous real replacement therapy: a randomized controlled trial. Crit Care, 2015, 19: 91.
|
27. |
Okuda A, Uchino S, Shibasaki T, et al. Experience of the continuous hemodialysis with citrate anticoagulation. J Jpn Soc Intensive Care Med, 2013(20): 653-654.
|